Abstract
Metastatic melanoma has a poor prognosis and until today most therapeutic approaches are ineffective. Advances in molecular pathology and genome analysis technologies have led to the identification of genetic events and immune regulatory checkpoints that provide novel targets for pharmaceutical intervention in melanoma. Development of selective mitogen-activated kinase (MAPK) pathway inhibitors was the first major achievement coming from genetic studies that identified a constitutively active MAP kinase pathway and BRAF activating mutations in melanoma. At the same time, the manipulation of immune system checkpoints through monoclonal antibodies changed clinical practice and led to further improvement of patient outcomes. In an effort to further develop melanoma targeted therapies that depend on the genetic profile of a given patient, high-throughput genome wide approaches (next-generation sequencing [NGS], gene arrays, etc) have been employed for the characterization of genetic alterations in the patient’s tumor. In the near future, the combined information from the genetic and immune background of an individual will provide the basis for a personalized, highly targeted approach in the treatment of melanoma.
Keywords: Arrays, BRAF inhibitors, immunotherapy, MAPK, melanoma, post-genomic Era.
Current Molecular Pharmacology
Title:Current Therapeutic Leads for the Treatment of Melanoma: Targeted Immunotherapy in the Post-genomic Era
Volume: 7
Author(s): Anastasios D. Papanastasiou, Chaido Sirinian, Haralabos P. Kalofonos and Maria Repanti
Affiliation:
Keywords: Arrays, BRAF inhibitors, immunotherapy, MAPK, melanoma, post-genomic Era.
Abstract: Metastatic melanoma has a poor prognosis and until today most therapeutic approaches are ineffective. Advances in molecular pathology and genome analysis technologies have led to the identification of genetic events and immune regulatory checkpoints that provide novel targets for pharmaceutical intervention in melanoma. Development of selective mitogen-activated kinase (MAPK) pathway inhibitors was the first major achievement coming from genetic studies that identified a constitutively active MAP kinase pathway and BRAF activating mutations in melanoma. At the same time, the manipulation of immune system checkpoints through monoclonal antibodies changed clinical practice and led to further improvement of patient outcomes. In an effort to further develop melanoma targeted therapies that depend on the genetic profile of a given patient, high-throughput genome wide approaches (next-generation sequencing [NGS], gene arrays, etc) have been employed for the characterization of genetic alterations in the patient’s tumor. In the near future, the combined information from the genetic and immune background of an individual will provide the basis for a personalized, highly targeted approach in the treatment of melanoma.
Export Options
About this article
Cite this article as:
Papanastasiou D. Anastasios, Sirinian Chaido, Kalofonos P. Haralabos and Repanti Maria, Current Therapeutic Leads for the Treatment of Melanoma: Targeted Immunotherapy in the Post-genomic Era, Current Molecular Pharmacology 2014; 7 (1) . https://dx.doi.org/10.2174/187446720701150105171803
DOI https://dx.doi.org/10.2174/187446720701150105171803 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chromatin Remodeling Agents for Cancer Therapy
Reviews on Recent Clinical Trials Therapeutic Targeting of TRP Channels - The TR(i)P to Pain Relief
Current Topics in Medicinal Chemistry Prader-Willi Syndrome: Clinical Genetics and Diagnostic Aspects with Treatment Approaches
Current Pediatric Reviews Thermal Assisted In Vivo Gene Electrotransfer
Current Gene Therapy Bioinformatic Application in Proteomic Research on Biomarker Discovery and Drug Target Validation
Current Bioinformatics ADAM9 as a Potential Target Molecule in Cancer
Current Pharmaceutical Design An Expanding Appreciation of the Role Chemokine Receptors Play in Cancer Progression
Current Pharmaceutical Design Linking Inflammation to Cell Cycle Progression
Current Pharmaceutical Design Assembled Core-Shell Nanostructures of Gold Nanoparticles with Biocompatible Polymers Toward Biology
Current Topics in Medicinal Chemistry New Development and Application of Ultrasound Targeted Microbubble Destruction in Gene Therapy and Drug Delivery
Current Gene Therapy Surgical Strategies for Fertility Preservation in Women with Cancer
Current Women`s Health Reviews Cyclooxygenase-2 Biology
Current Pharmaceutical Design HIV-1 Infection: Recent Developments in Treatment and Current Management Strategies
Anti-Infective Agents in Medicinal Chemistry NF-κB Blockers Gifted by Mother Nature: Prospectives in Cancer Cell Chemosensitization
Current Pharmaceutical Design Structure Guided Molecular Docking Assisted Alignment Dependent 3DQSAR Study on Steroidal Aromatase Inhibitors (SAIs) as Anti-breast Cancer Agents
Letters in Drug Design & Discovery HLA Associations with Nasopharyngeal Carcinoma
Current Molecular Medicine Targeting the JAK/STAT Signaling Pathway for Breast Cancer
Current Medicinal Chemistry The Synergistic Effects of DNA-Targeted Chemotherapeutics and Histone Deacetylase Inhibitors As Therapeutic Strategies for Cancer Treatment
Current Medicinal Chemistry The Role for Oxidative Stress in Aberrant DNA Methylation in Alzheimer’s Disease
Current Alzheimer Research Management of Glioblastoma Multiforme by Phytochemicals: Applications of Nanoparticle-Based Targeted Drug Delivery System
Current Drug Targets